Terms: = Sarcomas AND SSX4, MGC119056, 6759, ENSG00000204645, O60224, MGC12411 AND Prognosis
4 results:
1. Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data.
Li F; Li J; Yu J; Pan T; Yu B; Sang Q; Dai W; Hou J; Yan C; Zang M; Zhu Z; Su L; Li YY; Liu B
EBioMedicine; 2021 Jul; 69():103436. PubMed ID: 34157484
[TBL] [Abstract] [Full Text] [Related]
2. Synovial Sarcoma: Advances in Diagnosis and Treatment Identification of New Biologic Targets to Improve Multimodal Therapy.
El Beaino M; Araujo DM; Lazar AJ; Lin PP
Ann Surg Oncol; 2017 Aug; 24(8):2145-2154. PubMed ID: 28397189
[TBL] [Abstract] [Full Text] [Related]
3. Primary pleuropulmonary and mediastinal synovial sarcoma: a clinicopathologic and molecular study of 26 genetically confirmed cases in the largest institution of southwest China.
Lan T; Chen H; Xiong B; Zhou T; Peng R; Chen M; Ye F; Yao J; He X; Wang Y; Zhang H
Diagn Pathol; 2016 Jul; 11(1):62. PubMed ID: 27401493
[TBL] [Abstract] [Full Text] [Related]
4. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.
Taylor BJ; Reiman T; Pittman JA; Keats JJ; de Bruijn DR; Mant MJ; Belch AR; Pilarski LM
J Immunother; 2005; 28(6):564-75. PubMed ID: 16224274
[TBL] [Abstract] [Full Text] [Related]
